Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62022TJ0175

    Judgment of the General Court (Eighth Chamber) of 15 March 2023.
    Novartis AG v European Union Intellectual Property Office.
    EU trade mark – Invalidity proceedings – EU word mark BREZTRI – Earlier EU word marks ONBREZ, BREZILIZER and BREEZHALER – No likelihood of confusion – Lack of enhanced distinctiveness of the earlier marks – Article 60(1)(a) and Article 8(1)(b) of Regulation (EU) 2017/1001 – Article 27(3)(b) of Regulation (EU) 2018/625.
    Case T-175/22.

    ECLI identifier: ECLI:EU:T:2023:135

     Judgment of the General Court (Eighth Chamber) of 15 March 2023 –
    Novartis v EUIPO – AstraZeneca (BREZTRI)

    (Case T‑175/22) ( 1 )

    (EU trade mark – Invalidity proceedings – EU word mark BREZTRI – Earlier EU word marks ONBREZ, BREZILIZER and BREEZHALER – No likelihood of confusion – Lack of enhanced distinctiveness of the earlier marks – Article 60(1)(a) and Article 8(1)(b) of Regulation (EU) 2017/1001 – Article 27(3)(b) of Regulation (EU) 2018/625)

    1. 

    EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Existence of an identical or similar earlier mark registered for identical or similar goods or services – Likelihood of confusion with the earlier mark – Enhanced distinctiveness of the earlier mark – Criteria for assessment

    (European Parliament and Council Regulation 2017/1001, Arts 8(1)(b) and 60(1)(a))

    (see paragraphs 15, 16, 74-77, 88, 89, 94)

    2. 

    EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Existence of an identical or similar earlier mark registered for identical or similar goods or services – Likelihood of confusion with the earlier mark – Assessment of the likelihood of confusion – Determination of the relevant public – Attention level of the public – Medicinal products

    (European Parliament and Council Regulation 2017/1001, Arts 8(1)(b) and 60(1)(a))

    (see paragraphs 18, 22, 91)

    3. 

    EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Existence of an identical or similar earlier mark registered for identical or similar goods or services – Likelihood of confusion with the earlier mark – Word mark BREZTRI – Word marks ONBREZ, BREZILIZER and BREEZHALER

    (European Parliament and Council Regulation 2017/1001, Arts 8(1)(b) and 60(1)(a))

    (see paragraphs 25, 39, 48, 50, 52, 61, 63, 65, 82-84, 101)

    4. 

    EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Existence of an identical or similar earlier mark registered for identical or similar goods or services – Similarity of the marks concerned – Criteria for assessment – Composite mark – Assessment of the distinctive character of an element of which a trade mark is composed

    (European Parliament and Council Regulation 2017/1001, Arts 8(1)(b) and 60(1)(a))

    (see paragraphs 26, 29, 30, 38, 47, 51)

    5. 

    EU trade mark – Decisions of EUIPO – Legality – Examination by the EU judicature – Criteria

    (European Parliament and Council Regulation 2017/1001)

    (see paragraph 37)

    6. 

    EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Existence of an identical or similar earlier mark registered for identical or similar goods or services – Likelihood of confusion with the earlier mark – Likelihood of association – Earlier marks exhibiting characteristics enabling them to be regarded as forming part of the same series or family – Conditions

    (European Parliament and Council Regulation 2017/1001, Arts 8(1)(b) and 60(1)(a))

    (see paragraphs 97-99)

    Operative part

    The Court:

    1. 

    Dismisses the action;

    2. 

    Orders Novartis AG to pay the costs.


    ( 1 ) OJ C 207, 23.5.2022.

    Top